The CEO of Abogen Biosciences will attend the mRNA Therapeutics Summit in Europe
Dr. Bo Ying, the founder, chairman and chief executive officer (CEO) of Abogen Biosciences, will attend the 4th mRNA-Based Therapeutics Summit Europe in Frankfurt, Germany in January 2025. As an invited expert speaker of the CEO & Global Leaders Think Tank, Dr. Ying will join the CEOs of other international mRNA pharmaceutical companies and the global leader of well-known biopharmaceutical company to discuss the future of mRNA therapeutics on the first day of the summit. Moreover, he will present the latest clinical progress of mRNA-based therapeutic cancer vaccines in the plenary session.
Figure 1: Dr. Bo Ying, CEO of Abogen Biosciences
As a globally renowned industrial summit in the field of mRNA-based drug research and development, the "mRNA-Based Therapeutics Summit" has been held for several consecutive sessions. This year's theme, "Revolutionising the Next Wave of mRNA Medicines Towards Clinical Reality", will bring together over 40 distinguished speakers from globally renowned pharmaceutical enterprises (such as Moderna, BioNTech, CureVac, GSK, Sanofi, etc.) to jointly discuss the latest progress and future trends of mRNA therapies. The summit is expected to attract more than 200 experts, scholars, and industry representatives in the global mRNA field.
Figure 2: The 4th mRNA-Based Therapeutics Summit Europe
Dr. Bo Ying’s Key Sessions
1. Plenary Session
Time: 8:30 AM, January 30, 2025
Topic: Technical & Clinical Progress in mRNA Therapeutics Beyond COVID-19 Vaccine
Overview: Dr. Ying will demonstrate how Abogen Biosciences utilizes its leading mRNA and lipid nanoparticle (LNP) platforms to promote the development of mRNA cancer therapeutic vaccines and share the future perspectives of mRNA-based therapeutics.
2. CEO & Global Leaders Think Tank
Time: 8:25 AM, January 29, 2025
Topic: Unlocking the Next Frontiers of mRNA-Based Vaccines & Therapeutics to Ensure Better Drugs Reach Patients Faster
Overview: Dr. Ying will be on the same stage with CEOs of globally renowned mRNA pharmaceutical companies including CureVac, Mercurna, Pantherna Therapeutics and the global leader of the well-known biopharmaceutical company Sanofi to jointly discuss the development blueprint and industry direction of mRNA-based therapeutics.
Abogen Biosciences: An Industry Pioneer Gaining Global Recognition
The conference agenda highlights that 49 clinical trials of mRNA vaccine and therapeutics have been initiated globally in 2024, signaling a new wave of treatments now beyond COVID-19. Notably, Abogen Biosciences will share its first-in-human trial progress alongside CureVac, Ethris and University College London at the conference, which is deemed “SESSIONS YOU CANNOT MISS”.
For more information about the conference, please visit the official website: http://www.mrnabased-therapeutics-europe.com/.
